Celon Pharma (LTS:0RKX) GF Score: 48/100 (As of Jul. 13, 2026) — 26% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKX Celon Pharma SA LTS:0RKX
48 GF Score
Price zł22.50
GF Value zł26.68
! 3 Warning Signs
View Full Analysis

What is Celon Pharma GF Score?

Celon Pharma LTS:0RKX 48 GF Score is 48 as of Jul. 13, 2026, which is 26% below its 10-year median of 65.00. GuruFocus rates LTS:0RKX with a GF Score™ of 48/100 and a GF Value™ of zł26.68. The stock has 3 warning signs investors should review.

Celon Pharma has the GF Score of 48, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 2/10
3. Growth Rank : 0/10
4. GF Value Rank : 10/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Celon Pharma might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Celon Pharma  (LTS:0RKX) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Celon Pharma GF Score Related Terms

LTS:0RKX vs ZTS, UTHR, VTRS: GF Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celon Pharma GF Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's GF Score distribution charts can be found below:

* The bar in red indicates where Celon Pharma's GF Score falls into.


LTS:0RKX
48GF Score
Celon Pharma SA LTS:0RKX
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 48 mean?
Celon Pharma (LTS:0RKX) has a GF Score of 48 as of Jul. 13, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Celon Pharma and its competitors. This is 26% below median its historical median of 65.00. Over the past decade, Celon Pharma's GF Score has ranged from 23.00 to 84.00.
Is Celon Pharma's GF Score too high?
Celon Pharma's current GF Score of 48 is 26% below median its 10-year median of 65.00. Over the past 10 years, this metric has ranged from a low of 23.00 to a high of 84.00. Overall, Celon Pharma has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's GF Score compare to ZTS and UTHR?
Celon Pharma's GF Score of 48 can be compared against companies in the Drug Manufacturers industry. Historically, Celon Pharma's own GF Score has ranged from 23.00 to 84.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Celon Pharma and its competitors. Celon Pharma's current GF Score is 48, which is 26% below median its own 10-year median of 65.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current GF Score of 48. The stock's GF Value™ is zł26.68, compared to a current price of zł22.50 — trading 15.7% below its estimated fair value. The current GF Score is 48, which is 26% below median its 10-year median of 65.00. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current GF Score is 48 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (LTS:0RKX) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł22.50 is trading 15.7% below its estimated GF Value™ of zł26.68.

Key valuation signals for LTS:0RKX:

  • GF Score: 48 (26% below median its 10-year median of 65.00)
  • GF Value™: zł26.68 vs. price of zł22.50 (15.7% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges CLN:Poland8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score

Get the complete analysis for LTS:0RKX

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł22.50
Price
zł26.68
GF Value